Harrow (HROW) Non-Current Debt (2011 - 2026)
Harrow (HROW) posted Non-Current Debt of $292.4 million for Q2 2026, little changed on a QoQ basis from $292.1 million in Q1 2026, and up 659.74% year-over-year from $38.5 million in Q2 2025.
Analysis
Harrow (HROW) Non-Current Debt (2011 - 2026) Analysis & Trends
Harrow has reported Non-Current Debt for 13 years, with the latest figure at $292.4 million in Q2 2026.
- On a quarterly basis, Non-Current Debt rose 659.74% year-over-year to $292.4 million in Q2 2026; TTM through Jun 2026 was $292.4 million, a 659.74% increase from a year earlier, with the FY2025 full-year figure at $243.2 million, up 10.77% from the prior year.
- Non-Current Debt was $292.4 million for Q2 2026 at Harrow, roughly flat from $292.1 million in the prior quarter.
- The five-year high for Non-Current Debt was $292.4 million in Q2 2026, with the low at $38.5 million in Q2 2025.
- Average Non-Current Debt over 5 years is $168.0 million, with a median of $183.2 million recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: Non-Current Debt sank 79.2% in 2025, then surged 659.74% in 2026.
- Over 5 years, Non-Current Debt stood at $104.2 million in 2022, then surged by 78.44% to $185.9 million in 2023, then rose by 18.1% to $219.5 million in 2024, then advanced by 10.77% to $243.2 million in 2025, then climbed by 20.23% to $292.4 million in 2026.
- The last three Non-Current Debt figures came in at $292.4 million (Q2 2026), $292.1 million (Q1 2026), and $243.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.04 Bn | 624.28 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 440.25 Bn | 433.68 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 365.65 Bn | 358.51 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 266.64 Bn | 258.95 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 60.50 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 17.02 Bn |
| 7 | Revolution Medicines | 44.19 Bn | 44.19 Bn | - | - |
| 8 | Incyte | 25.29 Bn | 20.75 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | - |
| 10 | Harrow | 1.41 Bn | 1.33 Bn | 50.36 Mn | 292.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 292.38 Mn |
| Mar 31, 2026 | 292.09 Mn |
| Dec 31, 2025 | 243.18 Mn |
| Sep 30, 2025 | 242.87 Mn |
| Jun 30, 2025 | 38.48 Mn |
| Mar 31, 2025 | 112.50 Mn |
| Dec 31, 2024 | 219.54 Mn |
| Sep 30, 2024 | 186.06 Mn |
| Jun 30, 2024 | 185.02 Mn |
| Mar 31, 2024 | 184.15 Mn |
| Dec 31, 2023 | 185.89 Mn |
| Sep 30, 2023 | 182.19 Mn |
| Jun 30, 2023 | 169.71 Mn |
| Mar 31, 2023 | 168.85 Mn |
| Dec 31, 2022 | 104.17 Mn |
| Sep 30, 2022 | 72.24 Mn |
| Jun 30, 2022 | 72.04 Mn |
| Mar 31, 2022 | 71.85 Mn |
| Dec 31, 2021 | 71.65 Mn |
| Sep 30, 2021 | 71.46 Mn |